文献速递神经肿瘤

脑肿瘤诊疗中高级分子检测的医学必要性

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
PubMed 文献 · Neuro Oncol · 2019-01-01

本文综述脑肿瘤分子检测的障碍、推荐工具及数据解读,强调2016年WHO中枢神经系统肿瘤分类纳入分子标准及NCCN指南更新,但各机构分子诊断可及性与使用差异大且报销不足是主要障碍。

要点

  • 脑肿瘤分子检测是精准诊疗的医学必要组成部分
  • WHO 2016分类与NCCN指南已纳入分子标准
  • 报销缺乏与机构差异阻碍分子诊断的普及

核心结论

  • 脑肿瘤分子检测对准确病理诊断和分子指导治疗决策具有医学必要性,但可及性和报销障碍仍需解决。

研究设计与样本

  • 综述,旨在识别脑肿瘤分子检测的障碍、描述当前推荐的分子工具并总结分子数据解读以指导临床。

主要发现

  • 各机构间分子诊断的可及性和使用仍高度可变,缺乏报销仍是显著障碍。

关键数值与推荐

  • 2016年WHO中枢神经系统肿瘤分类纳入了分子标准。
  • 美国国家综合癌症网络(NCCN)官方指南已更新纳入分子检测相关内容。

临床怎么用

  • 应依据WHO分类和NCCN指南,在成人和儿童脑肿瘤常规诊疗中合理采用分子检测以指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate pathologic diagnoses and molecularly informed treatment decisions for a wide variety of cancers depend on robust clinical molecular testing that uses genomic, epigenomic, and transcriptomic-based tools. Nowhere is this more essential than in the workup of brain tumors, as emphasized by the incorporation of molecular criteria into the 2016 World Health Organization classification of central nervous system tumors and the updated official guidelines of the National Comprehensive Cancer Network. Despite the medical necessity of molecular testing in brain tumors, access to and utilization of molecular diagnostics is still highly variable across institutions, and a lack of reimbursement for such testing remains a significant obstacle. The objectives of this review are (i) to identify barriers to adoption of molecular testing in brain tumors, (ii) to describe the current molecular tools recommended for the clinical evaluation of brain tumors, and (iii) to summarize how molecular data are interpreted to guide clinical care, so as to improve understanding and justification for their coverage in the routine workup of adult and pediatric brain tumor cases.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Horbinski C, Ligon KL, Brastianos P, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019. PMID: 31276167. doi:10.1093/neuonc/noz119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。